Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
- Associated Therapies
- -
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: AsparaginaseProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneProcedure: EchocardiographyDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: LestaurtinibDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneProcedure: Multigated Acquisition ScanDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoneDrug: Therapeutic HydrocortisoneDrug: Vincristine Sulfate
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 218
- Registration Number
- NCT00557193
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 78
- Registration Number
- NCT00551460
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸Saint Louis University Cancer Center, Saint Louis, Missouri, United States
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
- Conditions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 445
- Registration Number
- NCT00550992
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czechia
🇫🇷CHR Hotel Dieu, Nantes, France
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 38
- Registration Number
- NCT00548431
- Locations
- 🇩🇰
Department of Pediatrics, Rigshospitalet, Copenhagen, Denmark
🇩🇰Department of Pediatrics, University Hospital, Odense, Denmark
🇸🇪Department of Pediatrics, Drottning Sylvias Pediatric Hospital, Gothenburg, Sweden
LAL-BR/2001: Study Treatment to Low Risk ALL
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT00526175
- Locations
- 🇪🇸
Basurtuko Ospitalea, Basurto, Spain
🇪🇸Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸Hospital General de Alicante, Alicante, Spain
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-01-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00526305
- Locations
- 🇪🇸
Hospital General de Segovia, Segovia, Spain
🇪🇸Hospital Universitario de Canarias, Tenerife, Spain
🇪🇸H.U. Virgen del Rocio, Sevilla, Spain
Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT00501826
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2009-05-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 374
- Registration Number
- NCT00494897
- Locations
- 🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital general de Castellón, Castello, Castellón, Spain
🇪🇸Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 105
- Registration Number
- NCT00492856
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Illinois CancerCare - Havana, Havana, Illinois, United States
🇺🇸Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.